Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Pexidartinib (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 13 Sep 2017 Planned End Date changed from 1 Jun 2017 to 31 dec 2018.
- 13 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated